Production and pharmacologic modulation of the granulocyte-associated allergic responses to ovalbumin in murine skin models induced by injecting ovalbumin-specific Th1 or Th2 cells.
Because interferon-gamma, interleukin-4, and interleukin-5 have been identified at the mRNA and protein levels in the lesional skin of patients with atopic dermatitis, we investigated the roles played by granulocytes as effector cells in allergic inflammation by using two unique murine skin models. In vitro generated Th1 and Th2 cells from naïve splenocytes of antiovalbumin T cell receptor transgenic BALB/C mice were adoptively transferred with ovalbumin into the ear pinnae or air-pouches produced in the back skin of naïve, nontransgenic BALB/C mice. The injection of Th1 cells with ovalbumin induced delayed type ear swelling that peaked at 48 h, whereas that of Th2 resulted in ear swelling that peaked at a much earlier time, 24 h. Histologic study of the swollen ear skin and granulocytes recruited into the air-pouch demonstrated that, although the Th1-induced inflammation caused a neutrophil-predominant infiltrate with few eosinophils, larger numbers of eosinophils accumulated in the Th2-induced inflammation. Using these murine models, we further evaluated the effects of drugs used for the treatment of atopic diseases. The results showed that FK506 administration could effectively reduce skin inflammation induced by either Th cells. Interestingly, the neutrophil elastase inhibitor ONO-6818 efficiently inhibited Th1-induced inflammation. In contrast, a leukotriene receptor antagonist, ONO-1078, specifically suppressed Th2-induced inflammation. We also found that each ONO drug exerted direct influence on specified granulocytes, as neither affected in vitro production of relevant Th cytokines. Thus, we succeeded in developing animal skin inflammation models in which we can evaluate the contribution of protein antigen-specific Th1 or Th2 cells through the action of granulocytic effector cells.
Terui
T
T
Department of Dermatology, Tohoku University School of Medicine, Sendai, Japan. terui@mail.cc.tohoku.ac.jp
Sano
K
K
Okada
M
M
Shirota
H
H
Honda
M
M
Ozawa
M
M
Hirasawa
N
N
Tamura
G
G
Tagami
H
H
D000818:Animals; D002478:Cells, Cultured; D002867:Chromones / Q000494:pharmacology; D003876:Dermatitis, Atopic / Q000188:drug therapy / Q000276:immunology*; D004195:Disease Models, Animal; D004423:Ear; D004487:Edema / Q000188:drug therapy / Q000276:immunology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D004804:Eosinophils / Q000276:immunology*; D006967:Hypersensitivity / Q000188:drug therapy / Q000276:immunology; D007166:Immunosuppressive Agents / Q000494:pharmacology; D020024:Leukotriene Antagonists / Q000494:pharmacology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009504:Neutrophils / Q000276:immunology*; D010047:Ovalbumin / Q000276:immunology; D010069:Oxadiazoles / Q000494:pharmacology; D011744:Pyrimidinones / Q000494:pharmacology; D012867:Skin / Q000276:immunology; D016559:Tacrolimus / Q000494:pharmacology; D018417:Th1 Cells / Q000166:cytology / Q000276:immunology* / Q000637:transplantation; D018418:Th2 Cells / Q000166:cytology / Q000276:immunology* / Q000637:transplantation
D002867:Chromones; D004791:Enzyme Inhibitors; D007166:Immunosuppressive Agents; D020024:Leukotriene Antagonists; C419152:ONO 6818; D010069:Oxadiazoles; D011744:Pyrimidinones; D010047:Ovalbumin; C047681:pranlukast; D016559:Tacrolimus